The size of the European Renal Biomarkers market is forecasted to grow at a prominent CAGR during the forecast period. Europe is assumed as a developed market and is anticipated to witness significant growth in the forecast period.
The uplift in research and development activities for renal biomarkers, rising healthcare infrastructure, and escalating medical tourism impels the renal biomarkers market growth in Europe.
Growing pediatric suffering from renal diseases and government supports with funds are driving the market growth. The renal biomarkers market growth is driven by factors like the rising geriatric population and increasing demand for innovative healthcare products. Extensive usage in different diagnostic processes at reasonably low cost is commanding the growth of renal biomarkers in Europe. A high amount spent by the population on healthcare, development of personalized medicine for treating chronic kidney diseases, and early diagnosis of renal cancer may stop disease progression, which in turn escalates the renal biomarkers market growth in the region during the analysis period.
Difficulties associated with regulatory bodies and low reimbursement schemes are the factors impeding the market growth in Europe. No proper way or sufficient identification for examining acute and chronic kidney diseases is hampering the European renal biomarkers market.
This research report on the Europe Renal Biomarkers Market has been segmented and sub-segmented into the following categories:
By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe.Regional Analysis:
The market size of the renal biomarkers in Europe is estimated to grow with a high CAGR during the historical period from 2020 to 2025. Factors like the rising incidence of chronic kidney diseases like Acute Kidney Injury (AKJ), nephropathies, and drug-induced kidney toxicities leading to the enhancement of new renal biomarkers in regulating disease progression rate. The increasing occurrence rate of renal diseases and high blood pressure is escalating the growth of the market.
The UK is top in the region with the largest market share because of quick introduction and innovations in the market and equipment domain. A considerable increase in the aging population and booming dominance of disease illness, and a thriving interest in innovative work and investments in R&D will propel the market further.
Germany, France, Italy, and the rest of Europe are anticipated to have subsequent growth in the market of the region due to quick advances in genetics that tends to the development of advanced renal biomarkers in treating kidney diseases, strengthening the increase in the area.
Prominent Companies dominating the Europe Renal Biomarkers Market Profiled in the Report are Abbott Diagnostics, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Astute Medical Inc., Siemens Healthcare Diagnostics Inc., Thermo Fisher Scientific Inc., Alere Inc., bioMérieux SA, and Randox Laboratories Ltd.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Diagnostic Technique
5.1.1 Introduction
5.1.2 Chemiluminescent Enzyme Immunoassay
5.1.3 Colorimetric Assay
5.1.4 Enzyme-Linked Immunosorbent Assay
5.1.5 Liquid Chromatography-Mass Spectrometry
5.1.6 Particle-Enhanced Turbidimetric Immunoassay
5.1.7 Y-o-Y Growth Analysis, By Diagnostic Technique
5.1.8 Market Attractiveness Analysis, By Diagnostic Technique
5.1.9 Market Share Analysis, By Diagnostic Technique
5.2 Type
5.2.1 Introduction
5.2.2 Up-Regulated Proteins
5.2.2.1 Interleukin 18
5.2.2.2 Kidney injury molecule 1
5.2.2.3 Neutrophil gelatinase-associated lipocalin
5.2.3 Functional Biomarker
5.2.3.1 Serum Creatinine
5.2.3.2 Serum Cystatin C
5.2.3.3 Urine Albumin
5.2.4 Others
5.2.5 Y-o-Y Growth Analysis, By Type
5.2.6 Market Attractiveness Analysis, By Type
5.2.7 Market Share Analysis, By Type
5.3 End User
5.3.1 Introduction
5.3.2 Diagnostic Labs
5.3.3 Hospitals
5.3.4 Outpatient Clinics
5.3.5 Research Centres
5.3.6 Y-o-Y Growth Analysis, By End User
5.3.7 Market Attractiveness Analysis, By End User
5.3.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Diagnostic Technique
6.1.3.3 By Type
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Diagnostic Technique
6.1.4.3 By Type
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Diagnostic Technique
6.1.5.3 By Type
6.1.5.4 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
6.7 Rest of Europe
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Thermo Fisher Scientific Inc
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Abbott Laboratories
8.3 Beckman Coulter, Inc.
8.4 Randox Laboratories Ltd
8.5 Astute Medical Inc.
8.6 F. Hoffmann-La Roche AG
8.7 Siemens Healthcare Diagnostics Inc.
8.8 Alere Inc.
8.9 bioMérieux SA
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
